Olivier Lairez
Toulouse, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 244 publications
Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial.
Journal: JAMA cardiology
Published: August 19, 2026
Relative apical sparing of left ventricular longitudinal strain for the diagnosis of cardiac amyloidosis: a systematic review and meta-analysis.
Journal: Open heart
Published: March 31, 2026
Comorbidity Burden in Transthyretin Amyloidosis With Cardiomyopathy: Insights From the HELIOS-B Trial.
Journal: JACC. Heart failure
Published: March 27, 2026
Longitudinal changes in NT-proBNP after breast cancer radiotherapy: clinical determinants of its trajectory and association with cardiac dysfunction (BACCARAT study).
Journal: Clinical and translational radiation oncology
Published: March 05, 2026
Prognostic impact of right ventricular to pulmonary arterial coupling for patients undergoing surgery for severe mitral regurgitation.
Journal: European heart journal. Imaging methods and practice
Published: December 13, 2025
Idiopathic pericarditis in 2025: Advances in diagnosis and therapeutic strategies.
Journal: Autoimmunity reviews
Published: November 29, 2025
Evaluation of a combined symptom-based questionnaire and capillary natriuretic peptides testing for early detection of heart failure: a Heart Failure Awareness Days nationwide screening study (DEPIC FR).
Journal: European heart journal. Quality of care & clinical outcomes
Published: October 13, 2025
Cardiac amyloidosis across the spectrum of left ventricular function: multimodal functional and prognostic insights.
Journal: Heart (British Cardiac Society)
Published: September 25, 2025
Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial.
Journal: Nature medicine
Published: September 18, 2025
Effect of mavacamten on sudden cardiac death risk scores in obstructive hypertrophic cardiomyopathy.
Effect of mavacamten on sudden cardiac death risk scores in obstructive hypertrophic cardiomyopathy.
Journal: ESC heart failure
Published: September 04, 2025
Last Updated: 09/26/2026